Opioid Peptides: Potential for Drug Development by Aldrich, Jane V. & McLaughlin, Jay P.
Opioid Peptides: Potential for Drug Development
Jane V. Aldrich1,* and Jay P. McLaughlin2
1Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS 66045
2Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL 34987
Abstract
Opioid receptors are important targets for the treatment of pain and potentially for other disease
states (e.g. mood disorders and drug abuse) as well. Significant recent advances have been made
in identifying opioid peptide analogs that exhibit promising in vivo activity for treatment of these
maladies. This review focuses on the development and evaluation of opioid peptide analogs
demonstrating activity after systemic administration, and recent clinical evaluations of opioid
peptides for possible therapeutic use.
Introduction
The endogenous ligands for opioid receptors are peptides. Since their initial discovery in the
1970s, there have been extensive studies of the structure-activity relationships (SAR) of
opioid peptides for each of the opioid receptors (see refs. [1, 2] for reviews). However, the
evaluation of opioid peptide analogs in vivo has been limited, typically to examination of
activity following central (intrathecal, i.t., or intracerebroventricular, i.c.v.) administration.
Relatively few opioid peptide analogs have been evaluated following more clinically
relevant systemic (e.g., by subcutaneous, s.c., or oral, p.o.) routes of administration. This
review focuses on reports of the analgesic and other behavioral effects of opioid peptides in
animals following systemic administration, structural modifications that enhance the
systemic activity of opioid peptide analogs, and also recent clinical trials of opioid peptides.
The reader is referred to other recent reviews [2-5] for more detailed discussions on the
development of these and other opioid peptides.
Development of systemically active opioid peptides
Given the importance of mu opioid receptor (MOR) agonists such as morphine as
analgesics, the primary focus for opioid peptide analog development has been for the
treatment of pain, although a few opioid peptides have been examined for other applications
(see Table 1 and below). The emphasis in the majority of cases has been to induce analgesia
through activation of opioid receptors in the central nervous system (CNS), although
peripheral opioid receptor activation, particularly of kappa opioid receptors (KOR) [6], can
also mediate analgesic activity (see below). In order to develop opioid peptide analogs as
potential drugs they must be active after dosing by a clinically relevant route, typically by a
form of systemic administration. There has been interest in examining opioid peptide
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analogs for systemic, including oral, activity in antinociceptive assays in animals for more
than 20 years [7], with a number of peptides identified recently with improved
pharmacokinetic properties. This review discusses these advancements in recent years in the
search for opioid peptide analogs that are active after systemic administration.
Opioid peptides exhibiting activity after systemic administration in animals
An early successful demonstration of opioid peptides that exhibited activity after systemic
administration were analogs of dermorphin (Figure 1), an endogenous opioid peptide
obtained from amphibian skin that exhibits high selectivity for MOR. An early report [7]
described analogs of the N-terminal tetrapeptide, which appears to be the minimum
sequence from dermorphin required for agonist activity, that contained D-Arg at position 2
and that exhibited antinociceptive activity after both s.c. and oral administration. More
recently, the dermorphin tetrapeptide analog ADAMB (Figure 1) was designed by
incorporating modifications, including N-terminal quanidylation, from several dermorphin
tetrapeptides that exhibited weak oral analgesic activity. ADAMB was 4- and 38-fold more
potent as an analgesic than morphine following oral and s.c. administration, respectively
(see Table 2), and lasted more than twice as long [8]. While the peptide was reasonably
potent after oral administration (ED50 = 5.8 mg/kg in mice), its potency by this route was
65-fold lower than observed after s.c. administration, suggesting relatively low
bioavailability by the oral route.
The best studied of the tetrapeptide analogs containing D-Arg2 is Dmt-DALDA (Dmt-D-
Arg-Phe-LysNH2, Dmt = 2′,6′-dimethyltyrosine; see ref. [4] for a review). This peptide is
much more potent and demonstrates longer lasting analgesic activity than morphine when
administered subcutaneously. Tolerance developed to this peptide’s analgesic activity, but
interestingly it exhibited minimal cross tolerance in morphine-tolerant mice. Dmt-DALDA
is transported across Caco-2 monolayers, a model of the intestinal barrier, suggesting that
this peptide could be orally absorbed. Since blockade of delta opioid receptors (DOR) can
reduce morphine tolerance [4], Dmt-DALDA was linked to the DOR antagonist TICP[Ψ]
(Tyr-TicΨ[CH2HN]Cha-Phe, Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, Cha =
cyclohexylalanine) via an ethylenediamine linker at the C-termini in an effort to develop a
MOR agonist/DOR antagonist producing minimal tolerance and which can cross the blood-
brain barrier (BBB). The resulting peptide exhibited analgesic activity following s.c.
administration comparable to morphine (Table 2), but with a longer duration of activity and
substantially less tolerance [4].
Notably, recent reports suggest these opioid peptides containing D-Arg2 have an unusual
pharmacological profile that involves the release of endogenous opioid peptides, particularly
the endogenous KOR ligands the dynorphins. This could possibly result in a more favorable
side effect profile by minimizing liabilities such as respiratory depression and dependence
associated with traditional opioid analgesics (see ref. [9] for a review).
Structural modifications similar to those used in ADAMB, including N-terminal
guanidinylation, have been made to the MOR-selective endogenous mammalian opioid
peptide endomorphin-1 to enhance BBB penetration (see Figure 1) [10]. The four analogs
that contained D-Ala2 along with guanidindo-Tyr-D-Pro-Gly-Trp-Phe(p-Cl)NH2 each
exhibited modest antinociception after systemic administration (see Table 2) which was
blocked by naloxone administered i.c.v. but not by the peripherally-restricted antagonist
naloxone methiodide, suggesting that these peptides produced their effects through MOR in
the CNS.
The Dmt-Tic pharmacophore has been the basis of extensive SAR studies for opioid
receptor interaction, particularly for DOR [11]. The DOR system is associated with the
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regulation of emotional states (e.g., depression and anxiety), and although nonpeptide DOR
agonists have shown antidepressant and anxiolytic activity, they also produce convulsions
[12]. The peptidomimetic Dmt-Tic derivative UFP-512 (Figure 1) is a DOR selective
agonist that has been examined in vivo [13-15]. UFP-512, but not the DOR agonist Dmt-
Tic-NHCH2-Bid (UFP-502, Bid = 1H-benzimidazole), exhibited antidepressant-like activity
in the forced swimming test (Table 2) [14], suggesting that the CH2CO2 H functionality
conferred favorable pharmacokinetic properties, facilitating peptide transport across the
BBB. Notably, tolerance did not develop to the antidepressant-like activity in this assay after
7 days of chronic treatment [13]. This compound also exhibited anxiolytic activity in two
models following intraperitoneal (i.p.) administration [14]. Further studies of this
peptidomimetic in a rat model of Parkinson’s disease indicate a complex mechanism of
action, with lower doses facilitating locomotor activity while higher doses worsened
Parkinsonism-like symptoms, suggesting UFP-512 behaved as a partial agonist [15].
In contrast, the Dmt-Tic derivative Dmt-Tic-Lys-CH2-Ph (MZ-2) is an antagonist at both
MOR and DOR, blocking centrally administered morphine after both s.c. and oral
administration [16]; after oral administration it was approximately 4-fold less potent than
naloxone at antagonizing morphine in the hot plate test (Table 2). When MZ-2 was
administered daily at a low dose (0.01 mg/kg s.c.) that did not prevent morphine- or DOR
agonist-induced antinociception, it prevented the development of tolerance to morphine,
consistent with its antagonist activity at DOR. Subsequently it was shown that oral
administration of this peptidomimetic (10 mg/kg/day) could also reduce weight gain and
improve other obesity-related factors in obese mice [17].
Recently there has been an interest in bi- and multifunctional opioid peptide ligands with
activity at more than one target (see ref. [4] for a review). One approach has been to develop
peptides possessing both opioid agonist and neurokinin 1 antagonist activities, since a
neurokinin 1 antagonist was shown to attenuate the development of morphine tolerance (see
ref. [4]). One of these peptides, TY005, has recently been evaluated in vivo for
antinociceptive activity against nerve injury-induced hypersensitivity (i.e. antihyperalgesia)
following i.v. administration [18]. It was found to be more effective than morphine in this
model and did not lead to the development of analgesic tolerance.
Derivatives of the KOR endogenous opioid peptide dynorphin A have also been examined
for analgesic activity following systemic administration. The dynorphin A fragment
dynorphin A-(1-13) has been shown to exhibit antinociception in primates and humans in
addition to in rodents (see ref. [3] for a review). The dynorphin A-(1-8) analog E2078 has
been the most extensively studied in animals, and has also been administered to humans as
an analgesic (see ref. [3] for a review). A dynorphin A-(1-7) analog stabilized to
metabolism, SK-9709 (Figure 1), also exhibited antinociceptive activity following systemic
(s.c.) administration (Table 2) [19]. In addition, YFa, designed as a chimeric peptide
between Met5-enkephalin-Arg6-Phe7 and FMRFa (Phe-Met-Arg-Phe amide) with structural
similarities to dynorphin A, produced KOR-mediated antinociception in rats following i.p
administration without producing tolerance [20], although large doses (≥40 mg/kg) were
required. Structural modifications, i.e. D-Ala2 and/or Phe(p-Cl)4 incorporated into YFa to
enhance metabolic stability and improve BBB penetration, resulted in enhanced analgesic
potency following i.p. administration (see Table 2), but altered the opioid receptor
selectivity [21, 22]. Like the parent peptide, these analogs did not produce antinociceptive
tolerance. [NMeTyr1]dynorphin A-(1-13) and its C-terminal amide derivative have been
shown to enhance morphine-induced antinociception in morphine-tolerant rats after systemic
administration [23]. Interestingly, although the compounds were not active after s.c.
administration, they were active following pulmonary delivery.
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While the primary emphasis in the in vivo evaluation of opioid peptides has been for their
antinociceptive activity, opioid peptide analogs have other potential therapeutic applications
(see Box 1). We have recently demonstrated that the dynorphin A analog zyklophin (Figure
1), which is a highly KOR selective antagonist containing modifications that stabilize it to
metabolism, is not only active after systemic (s.c.) administration but can also antagonize
KOR in the CNS for a finite duration [24]. This peptide could have advantages over
nonpeptide KOR-selective antagonists, which exhibit unusually prolonged antagonist
activity (weeks after a single dose) [3]. Zyklophin also blocked drug seeking behavior in a
model of stress-induced reinstatement of cocaine abuse, suggesting that such KOR peptide
antagonists could have potential therapeutic applications in the treatment of drug abuse.
Box 1
Outstanding issues in the development of opioid peptides as therapeutic
agents
1. Delivery of peptide therapeutics and increasing bioavailability
The limited bioavailability of most peptides following oral administration has
limited the development of opioid peptides as therapeutic agents. The
demonstration of oral activity at reasonable doses for some opioid peptides
suggests the possibility in selected cases to develop orally active opioid
peptides, but it will be necessary to explore other routes of administration for a
number of therapeutically relevant peptides. The demonstrated activity of
dynorphin analogs following inhalation [23] suggest that it may be possible to
administer these peptides by other methods not involving injection that could
increase acceptance of such therapeutic agents.
2. Potential effects of species differences on blood-brain barrier permeability
The recent results for the central vs. peripheral activity of MMP-2200 in mice
vs. rhesus monkeys [27.28] illustrates one of the challenges in developing
centrally acting peptides. Because of their polar nature, peptides often cross
biological membranes by mechanisms other than passive diffusion, including
via specific transporters (see ref. [25]). Thus species differences could have a
greater impact on the distribution of peptides than for more hydrophobic small
molecules that penetrate the CNS by passive diffusion. Understanding species
differences in blood-brain barrier transport will also be important in the
development of opioid peptide ligands restricted to the periphery.
3. Side effect profiles of opioid peptides compared to corresponding nonpeptide
opioid ligands
Side effects, e.g. the convulsant activity of small molecule DOR agonists, have
limited the therapeutic development of some nonpeptide opioid ligands. In some
cases distinct differences have been demonstrated for opioid peptide ligands
compared to their nonpeptide counterparts, suggesting peptide opioid ligands
could exhibit different side effect profiles from small molecule ligands. The
high specificity of peptide ligands for opioid receptors can minimize off-target
side effects compared to small molecule ligands, and therefore additional
advantages of opioid peptide vs. nonpeptide ligands in terms of side effect
profiles could emerge as more in vivo results are reported.
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Chemical strategies to increase CNS penetration and stability of opioid peptides
Different approaches, including cationization (e.g. ADAMB), glycosylation and pegylation,
have been used to enhance the ability of opioid peptide analogs to penetrate the BBB along
with increasing their stability (see ref. [25] for a review). Glycosylation has been suggested
to enhance the potency of systemically administered peptides and to promote their
penetration across the BBB. Glycosylation of opioid peptides was initially reported over 20
years ago, and since then a variety of glycosylated opioid peptides have been synthesized
and examined for opioid activity (see ref. [26]). Recent results with glycosylated opioid
peptides, however, suggest that the effects of glycosylation on BBB penetration may be
species dependent. The Leu-enkephalin analog MMP-2200, which is a MOR/DOR agonist
that contains the disaccharide lactose attached to the side chain of serine at the C-terminus
(see Figure 1), produces antinociception activity in mice that is not blocked by the
peripherally-restricted opioid antagonist naloxone methiodide, verifying the involvement of
central opioid receptors in the antinociceptive activity in this species [27]; MMP-2200 also
exhibited less tolerance and less severe withdrawal symptoms compared to morphine. In
rhesus monkeys, however, this glycopeptide appears to act as a peripheral MOR/DOR
agonist with limited penetration into the CNS [28].
Pegylation has also been explored to enhance the analgesic potency of opioid peptides. In
the case of the DOR selective agonist cyclo[D-Pen2,D-Pen5]enkephalin (DPDPE), which is
cleared primarily by biliary excretion, N-terminal pegylation decreases hepatic clearance
and enhances analgesia following i.v. administration. This pegylated derivative appears to
function as a prodrug, undergoing hydrolysis to the parent peptide [29]. Attachment of 2
kDa poly(ethyleneglycol) (PEG) to the N-termini of the dimeric enkephalin analog biphalin
(Figure 1) enhanced antinociceptive activity somewhat following all routes of administration
examined (i.c.v., i.v., intramuscular, i.m., and s.c.; see Table 2) [30].
Recently, novel head-to-tail cyclic peptides have been reported that exhibit opioid activity.
[YpwFG], a cyclized derivative of endomorphin-1 containing a glycine bridge between Tyr1
and Phe4 (Figure 1) synthesized to enhance membrane permeability, exhibits antinociceptive
activity in mice following i.p. administration [31]. As expected, cyclization stabilizes the
peptide to metabolic degradation by proteases. Studies with the peripherally restricted
antagonist naloxone methiodide suggest that at lower doses the peptide produces
antinociception predominantly through peripheral MOR, and only at a higher dose (20 mg/
kg i.p.) does the peptide activate MOR in the CNS. In our laboratory we synthesized the
natural product cyclic tetrapeptide CJ-15,208 (cyclo[Phe-D-Pro-Phe-Trp]) [32] and found
that it exhibits potent antinociceptive activity in vivo in the 55° warm water tail withdrawal
assay in mice after either central (i.c.v.) (Ross, et al., submitted) or peripheral (i.p.)
administration.
Novel opioid peptides with sequences unrelated to the endogenous opioid peptides have also
been evaluated in animals (Table 2), and two analogs have undergone clinical trials (see
below). An all D tetrapeptide (D-Phe-D-Phe-D-Nle-D-ArgNH2), identified from a
combinatorial library, exhibits exceptional selectivity for KOR in vitro and appears to be
restricted primarily to the periphery after parental administration [33]. Because of the D
stereochemistry this peptide should be resistant to metabolism by proteases. Further
structural modification resulted in FE 200665 (now known as CR665) and a second analog
FE200666 that exhibit exceptional separation of antinociceptive activity from centrally
mediated side effects (e.g. sedation) [34]. CR665 and a third generation peptide CR845 have
been evaluated in clinical trials (see below).
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Opioid peptides examined in humans
Examination of dynorphin fragments and analogs in humans was initiated in the 1980’s and
1990’s when dynorphin A-(1-13) was evaluated for the treatment of severe pain and
suppression of opioid withdrawal symptoms following i.v. and i.t. delivery (see ref. [3] for a
review). The Dyn A-(1-8) analog E-2078 given intramuscularly was also evaluated in
humans and shown to have analgesic activity comparable to the clinically used small
molecule narcotic analgesic pentazocine in surgical patients (see ref. [3]). Recently, a novel
dynorphin A-(1-13) derivative CJC-1008, containing a maleimidopropionyl group to
promote its covalent attachment to serum albumin and to extend its duration of action, was
examined following i.v. infusion in a phase II clinical trial in postherpetic neuralgia patients
[35], and found to exhibit analgesic activity for at least 8, but for less than 24, hours.
As noted above, two all D tetrapeptide peripherally selective KOR agonists have undergone
clinical trials. CR665 (0.36 mg/kg i.v.) was evaluated in a double blind study on
experimental pain involving skin, muscle and viscera, and found to have a selective
analgesic effect on visceral pain, consistent with its peripheral KOR selective activity, in
contrast to the clinically used narcotic analgesic oxycodone which had a generalized effect
on all three types of pain [36]. A third generation analog CR845 has completed a Phase IIa
proof-of-concept clinical trial after a single i.v. infusion (0.040 mg/kg) to women following
laparoscopic hysterectomy (NCT00877799, http://clinicaltrials.gov) with positive results
reported in terms of pain relief and decrease in the incidence of undesirable side effects
(Cara Therapeutics press release, February 8, 2010, http://www.caratherapeutics.com/press-
releases.php).
In addition to the application of opioid peptides for the treatment of severe pain, the
endogenous opioid peptide Met5-enkephalin (referred to as opioid growth factor, OGF) has
been examined in Phase I and II clinical trials for the treatment of advanced pancreatic
cancer [37], based on its reported interaction with a target (the OGF receptor) that is distinct
from the classic opioid receptors and its inhibition of pancreatic cancer in cell culture and in
nude mice. This peptide (0.25 mg/kg i.v.) was reported to provide clinical benefit to 53% of
the patients who had failed standard chemotherapy, with a 3-fold increase in survival time.
Its efficacy is presently being examined against other cancers (Phase II clinical trials in head
and neck cancers, and Phase I clinical trial in hepatocellular cancer; http://clinicaltrials.gov,
see Table 2).
A novel approach to treat intractable pain that deserves mention is gene therapy with vectors
inducing expression of an endogenous opioid peptide. Replication defective herpes simplex
virus-based vectors have been used to express human proenkephalin and an engineered
endomorphin-2 gene in animal models, and have been shown to be particularly effective in
models of inflammatory and cancer pain. The results of the first small clinical trial with the
vector NP2 expressing proenkephalin have just been reported [38], and provided promising
results in terms of safety and pain relief.
Conclusions
Peptides have several advantages as potential drugs, including high activity, high specificity,
low toxicity, and minimization of drug-drug interactions [39]. However, challenges remain
in developing opioid peptides as potential therapeutic agents, particularly in terms of their
activity after systemic administration and their ability to cross the BBB (see Box 1).
Stabilizing these peptides to metabolism sufficiently to permit systemic administration can
be accomplished through a variety of structural modifications (see Figure 1) while still
retaining the desired pharmacological activity. The metabolic stability of the peptides can be
fine-tuned by the choice and number of modifications introduced. Often multiple
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modifications are necessary to produce significant activity following systemic
administration, as was the case with many of the peptides discussed here. However, other
factors in addition to metabolism, e.g. biliary excretion, can also limit the systemic
bioavailability of opioid peptide analogs.
A significant challenge in the development of opioid peptides for clinical use is optimizing
their distribution (or lack thereof) into the CNS (see Box 1). As described above, both
peptides that can cross the BBB (e.g. Dmt-DALDA and zyklophin) as well as peptides that
appear to be restricted to the periphery (e.g. CR665 and CR845) have been identified. The
mechanism of action and therapeutic application determines whether it will be necessary for
a drug to cross the BBB, or whether activity in the periphery is sufficient and indeed
advantageous. For the treatment of pain, agonists that are restricted to the periphery can
have distinct advantages because they should not exhibit centrally mediated undesirable side
effects (e.g. addiction) that severely limit the clinical use of existing therapeutics. In
contrast, for treatment of mood disorders and substance abuse, demonstration that the opioid
peptide analogs can cross the BBB is important for the development of these compounds as
potential therapeutic agents.
Multiple mechanisms have been implicated in the BBB penetration of opioid peptide
analogs [25]. Enhancing peptide lipophilicity can enhance BBB penetration by passive
diffusion [25], and the CNS penetration of several MOR selective peptides with different
structures was recently correlated with their lipophilicity [40]. However, other mechanisms
can be involved in transporting peptides across the BBB (see ref. [25]) or in limiting their
CNS penetration (i.e. efflux proteins such as P-glycoprotein [29]). Modifications such as
glycosylation or an N-terminal guanidyl group that enhance the hydrophilicity of peptides
have also been explored to increase BBB penetration. Unfortunately information on the CNS
penetration of opioid peptides is fragmentary and the evaluations performed used a variety
of different methods (see ref. [40]), making comparisons difficult and rational design of
CNS active peptides challenging. Moreover, apparent species differences in CNS
penetration of some peptides (see above, also Box 1) further complicates development of
CNS active peptides.
Delivery of therapeutic peptides remains a challenge (see Box 1), but recent advances, e.g.
in structural modification strategies, pulmonary delivery [23] and demonstrated activity
following oral administration, hold promise that opioid peptides can be systemically
administered by a variety of methods including those that don’t involve injection to yield
therapeutic benefit.
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Structures of opioid peptide analogs exhibiting systemic activity compared to the
endogenous opioid peptides. Structures of CJC-1008 and CR845 were not reported.
Abbreviations used are: Cha, cyclohexylalanine; Dap, 2,3-diaminoproprionic acid; Dmt, 2′,
6′-dimethyltyrosine; DPDPE, cyclo[D-Pen2,D-Pen5]enkephalin; Pen, penicillamine; Tic,
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; PEG, poly(ethylene glycol). Ψ[CH2NH]
denotes a reduced amide bond.
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Table 1
Potential therapeutic applications currently being explored for opioid peptides targeting different opioid
receptors.a
Opioid receptor activity Therapeutic application Example and reference
MOR agonistb Analgesia Dmt-DALDA plus several others – see text
DOR agonist Analgesia; anti-depressant and anxiolytic activity UFP-512 [13,15]
DOR antagonist
 Also in combination with MOR
agonist activity
Reduction in MOR agonist-induced tolerance MZ-2 [16]
Dmt-DALDA-CH2NH(TICPΨ) [4]
KOR agonist Peripherally restricted analgesics, especially for
visceral and inflammatory pain
CR665 [34, 36] and CR845




See ref. [6] for a review of DOR and KOR as drug targets
b
Also in combination with activity at other receptors, e.g. DOR or KOR agonist activity.
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